Effect of Genetic Polymorphisms on Platinum Based Chemotherapy in Non Small Cell Lung Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03154242
Recruitment Status : Unknown
Verified May 2017 by Esraa Salah Abdal Hay Abdal Khalek, Ain Shams University. Recruitment status was: Recruiting
First Posted : May 16, 2017
Last Update Posted : May 16, 2017
Ain Shams University
Information provided by (Responsible Party):
Esraa Salah Abdal Hay Abdal Khalek, Ain Shams University
This Study evaluate the effect of Polymorphism in the Excision repair cross-complementing group 5 (ERCC5) (rs1047768 and rs751402) gene on the clinical outcome of Platinum-based regimens used in the treatment of Non-Small Cell Lung Cancer (NSCLC) patients
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
clinical oncology department at Al Demerdash hospital
Newly diagnosed with immunohistochemically and pathologically confirmed non-small cell lung cancer (NSCLC).
Eastern Cooperative Oncology Group performance status (ECOG PS) = 0-2.
Age >18 years.
Adequate bone marrow reserve
Presence of Central nervous system(CNS) metastases.
Inadequate liver function
Inadequate renal function
Serious comorbid systemic disorder incompatible with the study.